Antibiotic Treatment for Community-Acquired Pneumonia

Introduction to Antibiotic Regimens

For a patient with Addison's disease and pneumonia, the recommended antibiotic regimen is a combination of a β-lactam (such as amoxicillin or ampicillin) plus a macrolide (such as clarithromycin or erythromycin) 1
The American Thoracic Society recommends combined therapy for community-acquired pneumonia (CAP) in hospitalized patients, especially those with advanced age and immunocompromised states like Addison's disease 1

First-line treatment for CAP in hospitalized patients is combined oral therapy with amoxicillin and a macrolide (erythromycin or clarithromycin) 1
If oral therapy is contraindicated, intravenous ampicillin or benzylpenicillin, together with erythromycin or clarithromycin, is recommended 1
For hospital-acquired pneumonia (HAP), a broad-spectrum β-lactamase stable antibiotic (co-amoxiclav, cefuroxime, or ceftriaxone) together with a macrolide (clarithromycin or erythromycin) is recommended as first-line treatment 1

For patients not at high risk of mortality, alternative treatment options include piperacillin-tazobactam 4.5g IV q6h, cefepime 2g IV q8h, levofloxacin 750mg IV daily, imipenem 500mg IV q6h, or meropenem 1g IV q8h 2
For patients at high risk of mortality, two antibiotics from different classes plus MRSA coverage with vancomycin or linezolid are recommended 2

Patients with Addison's disease require stress-dose steroids to ensure adequate steroid coverage during infection 1
Electrolyte monitoring is necessary to monitor for hyponatremia and hyperkalemia 1
Fluoroquinolones should be avoided if possible due to potential interactions with steroid replacement therapy 1

For non-severe pneumonia in patients with a penicillin allergy, a respiratory fluoroquinolone (levofloxacin 750mg daily) is recommended 3
For severe pneumonia in patients with a penicillin allergy, a fluoroquinolone with enhanced pneumococcal activity plus intravenous benzyl-penicillin is recommended 1

Clinical reassessment within 48-72 hours is essential to evaluate treatment response 1
If no improvement, consider adding a macrolide if on β-lactam monotherapy, changing to a respiratory fluoroquinolone if on combination therapy, or obtaining additional cultures and imaging 1